Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The role of pomalidomide-dexamethasone in patients with multiple myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the combination of lenalidomide and dexamethasone in multiple myeloma. Dr Cerchione explains that a recent retrospective study showed that this doublet was effective in heavily pre-treated patients who are not eligible for hospital-based treatment, and emphasizes the role of adequate supportive care in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.